© The Financial Times Ltd 2015 FT and 'Financial Times' are trademarks of The Financial Times Ltd.
As of May 22, 2015, the consensus forecast amongst 2 polled investment analysts covering GW Pharmaceuticals plc advises that the company will outperform the market. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Jul 28, 2014. The previous consensus forecast advised investors to purchase equity in GW Pharmaceuticals plc.
|Last year||3 months ago||2 months ago||4 weeks ago||Latest|
The 2 analysts offering 12 month price targets for GW Pharmaceuticals plc have a median target of 347.50, with a high estimate of 560.00 and a low estimate of 135.00. The median estimate represents a -44.40 % decrease from the last price of 625.00. View Full Financials
Dividend information is not available for GW Pharmaceuticals PLC. View Full Financials
On May 11, 2015, GW Pharmaceuticals plc reported 2nd quarter 2015 losses of -0.032 per share. This result exceeded the -0.070 consensus loss of the one analyst covering the company and exceeded last year's 2nd quarter results by 28.00%.
The next earnings announcement is expected on Aug 04, 2015. View Full Interim Financials
|Average growth rate||-78.29 %|
GW Pharmaceuticals plc reported annual 2014 losses of -0.070 per share on Dec 02, 2014. View Full Annual Financials
|Average growth rate||-61.50 %|
GW Pharmaceuticals plc had 2nd quarter 2015 revenues of 6.35m. This missed the 6.60m estimate of the one analyst following the company. The same period last year the company did not report revenues. View Full Interim Financials
|Average growth rate||-4.97 %|
GW Pharmaceuticals plc had revenues for the full year 2014 of 30.05m. This was 10.08% above the prior year's results. View Full Annual Financials
|Average growth rate||+0.21 %|